Eric J. Feldman

9.2k total citations · 1 hit paper
195 papers, 6.7k citations indexed

About

Eric J. Feldman is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Eric J. Feldman has authored 195 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Hematology, 82 papers in Molecular Biology and 52 papers in Genetics. Recurrent topics in Eric J. Feldman's work include Acute Myeloid Leukemia Research (108 papers), Chronic Myeloid Leukemia Treatments (39 papers) and Acute Lymphoblastic Leukemia research (34 papers). Eric J. Feldman is often cited by papers focused on Acute Myeloid Leukemia Research (108 papers), Chronic Myeloid Leukemia Treatments (39 papers) and Acute Lymphoblastic Leukemia research (34 papers). Eric J. Feldman collaborates with scholars based in United States, Canada and Germany. Eric J. Feldman's co-authors include Richard M. Stone, Gail J. Roboz, Alan F. List, Karen Seiter, Peter L. Greenberg, Tauseef Ahmed, Azra Raza, John M. Bennett, Jeffrey E. Lancet and Gordon W. Dewald and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Eric J. Feldman

188 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 893 citations Alan F. List, Gordon W. Dewald et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric J. Feldman United States	42	4.3k	3.0k	1.8k	1.4k	933	195	6.7k
Jeffrey E. Lancet United States	48	5.3k 1.2×	3.5k 1.2×	2.1k 1.1×	1.8k 1.3×	1.0k 1.1×	437	7.8k
B. Douglas Smith United States	43	4.2k 1.0×	2.8k 1.0×	1.5k 0.8×	1.3k 0.9×	947 1.0×	171	6.3k
Gail J. Roboz United States	46	5.0k 1.2×	3.6k 1.2×	2.0k 1.1×	1.6k 1.1×	929 1.0×	317	7.6k
Hitoshi Kiyoi Japan	46	5.4k 1.2×	4.4k 1.5×	2.0k 1.1×	2.1k 1.4×	1.4k 1.5×	277	9.0k
Adriano Venditti Italy	40	3.6k 0.8×	2.1k 0.7×	1.4k 0.7×	1.0k 0.7×	1.2k 1.3×	259	5.6k
Martin Höglund Sweden	37	3.4k 0.8×	1.5k 0.5×	1.6k 0.9×	1.2k 0.9×	1.1k 1.2×	134	5.1k
David A. Rizzieri United States	44	4.3k 1.0×	3.0k 1.0×	1.6k 0.9×	2.5k 1.7×	990 1.1×	309	8.1k
Maria Teresa Voso Italy	39	2.7k 0.6×	2.4k 0.8×	1.0k 0.6×	1.1k 0.8×	608 0.7×	239	5.3k
Sylvie Castaigné France	46	6.0k 1.4×	5.1k 1.7×	1.5k 0.8×	2.1k 1.5×	1.5k 1.7×	168	9.2k
David R. Head United States	35	6.5k 1.5×	3.2k 1.1×	1.5k 0.8×	2.0k 1.4×	3.1k 3.4×	90	8.8k

Countries citing papers authored by Eric J. Feldman

Since Specialization

Citations

This map shows the geographic impact of Eric J. Feldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Feldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Feldman more than expected).

Fields of papers citing papers by Eric J. Feldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Feldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Feldman. The network helps show where Eric J. Feldman may publish in the future.

Co-authorship network of co-authors of Eric J. Feldman

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Feldman. A scholar is included among the top collaborators of Eric J. Feldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Feldman. Eric J. Feldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hammami, M Bakri, Mendel Goldfinger, Nishi Shah, et al.. (2024). Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort. Transplantation and Cellular Therapy. 30(5). 544.e1–544.e8. 3 indexed citations

Feldman, Eric J., Brian Lu, John C. Lin, et al.. (2024). Utility of Activated Partial Thromboplastin Time Screening in Prospective Living Kidney Donors: A Single Center Cohort Study. Kidney Medicine. 7(3). 100951–100951. 1 indexed citations

Yan, John, M Bakri Hammami, Nishi Shah, et al.. (2024). Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database. Annals of Hematology. 103(9). 3543–3551.

Levitz, David, Yogen Saunthararajah, Lauren Shapiro, et al.. (2023). A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. Clinical Cancer Research. 29(15). 2774–2780. 10 indexed citations

Silverman, Lewis R., Amit Verma, Rosalie Odchimar-Reissig, et al.. (2013). A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium. Blood. 122(21). 386–386. 19 indexed citations

Ritchie, Ellen K., Eric J. Feldman, Paul J. Christos, et al.. (2012). Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leukemia & lymphoma. 54(9). 2003–2007. 101 indexed citations

Feldman, Eric J., Jonathan E. Kolitz, J M Trang, et al.. (2012). Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leukemia Research. 36(10). 1283–1289. 85 indexed citations

List, Alan F., Gordon W. Dewald, John M. Bennett, et al.. (2006). Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. New England Journal of Medicine. 355(14). 1456–1465. 893 indexed citations breakdown →

Roboz, Gail J., Francis J. Giles, Alan F. List, et al.. (2006). Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 20(6). 952–957. 65 indexed citations

10.

Seiter, Karen, Delong Liu, Eric J. Feldman, et al.. (2006). Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leukemia & lymphoma. 47(3). 425–432. 5 indexed citations

11.

Shore, Tsiporah B., John G. Harpel, Michael W. Schuster, et al.. (2006). A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy. Biology of Blood and Marrow Transplantation. 12(8). 868–875. 9 indexed citations

12.

Feldman, Eric J.. (2006). Farnesyltransferase inhibitors in myelodysplastic syndrome. Current Hematologic Malignancy Reports. 1(1). 20–24. 12 indexed citations

13.

Quan, Shuo, Eric J. Feldman, Liming Yang, et al.. (1999). Distinct Effect of Retroviral-Mediated IFN-alpha Gene Transfer on Human Erythroleukemic and CD34 ⁺ Cell Growth and Differentiation. Journal of Hematotherapy & Stem Cell Research. 8(5). 491–502. 2 indexed citations

14.

Quan, Shuo, Karen Seiter, Eric J. Feldman, et al.. (1999). Human CD34+ hematopoietic cells transduced by retrovirus-mediated interferon alpha gene maintains regeneration capacity and engraftment in NOD/SCID mice. Experimental Hematology. 27(10). 1511–1518. 3 indexed citations

15.

Ahmed, Tauseef, J. D. Lutton, Eric J. Feldman, et al.. (1998). Gene transfer of alpha interferon into hematopoietic stem cells. Leukemia Research. 22(2). 119–124. 8 indexed citations

16.

Feldman, Eric J.. (1997). High-dose mitoxantrone in acute leukaemia: New York Medical College experience. European Journal of Cancer Care. 6(s1). 27–32. 1 indexed citations

17.

Lake, Diana, et al.. (1996). Graft-versus-host disease: Possible higher risk for African American patients. Cancer. 78(7). 1492–1497. 13 indexed citations

18.

Lake, Diana, et al.. (1996). Graft‐versus‐host disease: Possible higher risk for African American patients. Cancer. 78(7). 1492–1497. 1 indexed citations

19.

Traganos, Frank, Karen Seiter, Eric J. Feldman, H. Dorota Halicka, & Zbigniew Darżynkiewicz. (1996). Induction of Apoptosis by Camptothecin and Topotecan. Annals of the New York Academy of Sciences. 803(1). 101–110. 24 indexed citations

20.

Puccio, Carmelo, Abraham Mittelman, Stuart M. Lichtman, et al.. (1991). A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.. Journal of Clinical Oncology. 9(9). 1562–1569. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact